Skip to main content

Advertisement

Table 3 Univariate Analyses

From: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation

Variable DFS [HR (95% CI)] OS [HR (95% CI)] pCR [OR (95% CI)]
NLR
 < 4 ref a a
 ≥ 4 1.24 (1.00–1.53)   
Age at diagnosis
 < 65 ref ref ref
 ≥ 65 1.34 (1.11–1.63) 1.77 (1.40–2.22) 0.72 (0.53–0.98(
ECOG PS
 0 ref ref ref
 1 1.53 (1.22–1.93) 1.81 (1.36–2.39) 0.72 (0.52–1.00)
 2+ 2.06 (1.37–3.10) 3.37 (2.17–5.25) 0.19 (0.06–0.63)
 Unknown 1.75 (1.33–2.31 2.04 (1.47–2.83) 0.79 (0.51–1.23)
Distance from anal verge
 < 5 cm ref ref a
 5–10 cm 0.92 (0.74–1.16) 0.90 (0.69–1.18)  
 > 10 cm 0.79 (0.59–1.05) 0.72 (0.51–1.02)  
 Unknown 1.49 (1.02–2.15) 1.52 (1.00–2.33)  
Pre-treatment CEA (ng/ml)
 < 5 ref ref ref
 ≥ 5 1.71 (1.39–2.11) 1.83 (1.43–2.34) 0.37 (0.26–0.54)
 Unknown 1.63 (1.21–2.19) 1.49 (1.04–2.13) 0.69 (0.43–1.12)
Clinical stage
 II ref ref ref
 III 1.21 (0.97–1.52) 1.07 (0.82–1.39) 0.66 (0.49–0.91)
 Unknown 3.35 (1.75–6.43) 4.14 (2.07–8.26) 0.25 (0.03–1.92)
 Hemoglobinb 0.99 (0.99–1.00) 0.99 (0.98–1.00) 1.01 (1.00–1.02)
Neoadjuvant chemotherapy
 5-fluorouracil ref ref a
 Capecitabine 1.30 (1.06–1.60) 1.27 (0.99–1.63)  
 Raltitrexed 0.56 (0.18–1.75) 0.52 (0.13–2.08)  
 Unknown 2.95 (1.82–4.76) 3.28 (1.90–5.65)  
Adjuvant chemotherapyc
 Not received ref ref N/A
 Received 0.63 (0.51–0.77) 0.45 (0.35–0.56) N/A
Provincec
 Alberta ref ref ref
 British Columbia 1.50 (1.19–1.90) 1.34 (1.02–1.75) 0.56 (0.37–0.86)
 Ontario 0.65 (0.51–0.84) 0.47 (0.35–0.64) 0.83 (0.60–1.16)
  1. CEA Carcinoembryonic antigen, ECOG PS Eastern Cooperative Oncology Group Performance Status, HR Hazard ratio, OR Odds Ratio
  2. Non-significant in univariate analysis: PLR, sex, year of diagnosis, body mass index, statin use, radiation dose
  3. aNo statistically significant results
  4. bMeasured as continuous variable
  5. cNon-proportional hazards